Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of STSA-1002 injection in acute respiratory distress syndrome
CTR20253968Phase 3Active
- Sponsor
- Staidson Biopharmaceutical
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of STSA-1002 in acute respiratory distress syndrome (ARDS), sponsored by Staidson Biopharmaceutical. Started Nov 2025; status: active.
02
Drugs
STSA-1002
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on CTR20253968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253968.